Rituximab
EAS |
Nº pacientes |
Respuesta terapéutica n (%) |
Efectos adversos n (%) |
Mortalidad |
|---|---|---|---|---|
CHURG-STRAUSS |
4 |
100 |
50 |
0 |
CRYOGLOBULINEMIA |
88 |
85,22 |
15,90 |
6 |
DERMATOMYOSITIS |
19 |
78,94 |
31,57 |
1 |
SYSTEMIC SCLEROSIS |
4 |
75 |
50 |
1 |
RPGN-ANCA |
1 |
100 |
0 |
0 |
HORTON |
2 |
100 |
50 |
0 |
SLE |
172 |
89,53 |
18,02 |
5 |
PAM |
9 |
100 |
0 |
0 |
RHEUMATIC POLIMYALGIA |
1 |
100 |
0 |
0 |
POLIMYOSITIS |
7 |
100 |
0 |
0 |
ANTISINTETASE SDR |
3 |
100 |
33,33 |
0 |
APS |
12 |
91,66 |
8,333 |
1 |
SARCOIDOSIS |
1 |
100 |
0 |
0 |
SJOGREN |
69 |
92,75 |
23,18 |
0 |
ADULT-ONSET STILL |
3 |
66,66 |
0 |
0 |
WEGENER |
68 |
86,76 |
22,05 |
0 |
| Total | 463 |
88,77 |
19,22 |
14 (3,02%) |